Danaher Corporation $DHR Shares Acquired by Net Worth Advisory Group

Net Worth Advisory Group increased its position in shares of Danaher Corporation (NYSE:DHR) by 399.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,328 shares of the conglomerate’s stock after purchasing an additional 3,462 shares during the quarter. Net Worth Advisory Group’s holdings in Danaher were worth $917,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Danaher in the 2nd quarter worth approximately $10,492,520,000. Jupiter Topco LLC bought a new stake in Danaher during the 2nd quarter worth approximately $1,456,317,000. Generation Investment Management LLP acquired a new stake in Danaher during the 2nd quarter valued at $1,287,949,000. Bank of America Corp DE acquired a new stake in Danaher during the 2nd quarter valued at $993,846,000. Finally, Legal & General Group Plc bought a new position in Danaher in the 2nd quarter valued at $801,056,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of DHR stock opened at $224.45 on Tuesday. The firm has a market cap of $157.78 billion, a price-to-earnings ratio of 39.87, a PEG ratio of 2.88 and a beta of 0.76. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average price of $214.35 and a 200 day moving average price of $196.30.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 EPS. Research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is currently 28.42%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DHR. Royal Bank Of Canada raised their target price on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Wells Fargo & Company decreased their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Stifel Nicolaus lowered their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Guggenheim upped their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.